245 related articles for article (PubMed ID: 15851788)
1. New combinations in metastatic colorectal cancer: what are our expectations?
Hurwitz H
Oncologist; 2005 May; 10(5):320-2. PubMed ID: 15851788
[No Abstract] [Full Text] [Related]
2. [The development of the first line treatment of metastatic colorectal cancer (mCRC)].
Landherr L; Nagykálnai T
Magy Onkol; 2009 Sep; 53(3):237-46. PubMed ID: 19793687
[TBL] [Abstract][Full Text] [Related]
3. [Metastatic colorectal cancer: adjournments from ESMO 2006].
Bonetti A; Cascinu S; Falcone A; Maiello E; Zaniboni A; Aschele C
Tumori; 2006; 92(6):1-12. PubMed ID: 17262903
[No Abstract] [Full Text] [Related]
4. Dual biologic therapy in the first-line mCRC setting: implications of the CAIRO2 study.
Chu E
Clin Colorectal Cancer; 2008 Jul; 7(4):226. PubMed ID: 18650190
[No Abstract] [Full Text] [Related]
5. Common side effects and interactions of colorectal cancer therapeutic agents.
Holt K
J Pract Nurs; 2011; 61(1):7-20. PubMed ID: 21751717
[No Abstract] [Full Text] [Related]
6. [Progress of chemotherapy in colorectal cancer].
Komatsu Y
Gan To Kagaku Ryoho; 2007 Nov; 34(11):1771-6. PubMed ID: 18064761
[No Abstract] [Full Text] [Related]
7. Short time infusion of bevacizumab in combination with 5FU-based chemotherapy as first-line therapy in a non-selective patient group with metastatic colorectal cancer.
Dohn LH; Jensen BV; Larsen FO
Acta Oncol; 2010 Apr; 49(3):395-6. PubMed ID: 20001495
[No Abstract] [Full Text] [Related]
8. Chemotherapy and immunotherapy in metastatic colorectal cancer.
Pohlmann PR; Mernaugh RL; Goff LW
N Engl J Med; 2009 May; 360(20):2134; author reply 2135-6. PubMed ID: 19439750
[No Abstract] [Full Text] [Related]
9. [Present status of chemotherapy for colorectal cancer in countries outside of Japan].
Doi T; Ohtsu A
Nihon Rinsho; 2003 Sep; 61 Suppl 7():368-73. PubMed ID: 14574915
[No Abstract] [Full Text] [Related]
10. Cost-effectiveness of targeted therapy with cetuximab in patients with K-ras wild-type colorectal cancer presenting with initially unresectable metastases limited to the liver in a German setting.
Asseburg C; Frank M; Köhne CH; Hartmann JT; Griebsch I; Mohr A; Osowski U; Schulten J; Mittendorf T
Clin Ther; 2011 Apr; 33(4):482-97. PubMed ID: 21635994
[TBL] [Abstract][Full Text] [Related]
11. [Advances in the treatment of metastatic colorectal cancer with bevacizumab].
Longo F; Mansueto G
Tumori; 2006; 92(5):suppl 1-12. PubMed ID: 17168449
[No Abstract] [Full Text] [Related]
12. [Systemic therapy for colorectal cancer].
Pestalozzi BC; Jäger D; Knuth A
Chirurg; 2005 Jun; 76(6):570-2, 574. PubMed ID: 15905968
[TBL] [Abstract][Full Text] [Related]
13. Always look at the bright side of drugs?
Nygren P
Acta Oncol; 2015 Feb; 54(2):145-7. PubMed ID: 25608927
[No Abstract] [Full Text] [Related]
14. Progress in the development of novel treatments for colorectal cancer.
Hoff PM; Pazdur R
Oncology (Williston Park); 2004 May; 18(6):705-8. PubMed ID: 15214591
[TBL] [Abstract][Full Text] [Related]
15. Metastatic colorectal cancer: is there one standard approach?
Saltz LB
Oncology (Williston Park); 2005 Aug; 19(9):1147-54; discussion 1154, 1157-8, 1160. PubMed ID: 16255132
[TBL] [Abstract][Full Text] [Related]
16. Highlights from the 42nd Annual Meeting of the American Society of Clinical Oncology, Atlanta, GA, June 2006.
Clin Colorectal Cancer; 2006 Jul; 6(2):109-13. PubMed ID: 16945165
[No Abstract] [Full Text] [Related]
17. [Transition of chemotherapy for metastatic colorectal cancer and recent advances].
Muro K
Nihon Rinsho; 2010 Jun; 68(6):1143-9. PubMed ID: 20535969
[TBL] [Abstract][Full Text] [Related]
18. Body surface area-based dosing of 5-fluoruracil results in extensive interindividual variability in 5-fluorouracil exposure in colorectal cancer patients on FOLFOX regimens.
Saam J; Critchfield GC; Hamilton SA; Roa BB; Wenstrup RJ; Kaldate RR
Clin Colorectal Cancer; 2011 Sep; 10(3):203-6. PubMed ID: 21855044
[No Abstract] [Full Text] [Related]
19. Chemotherapy and immunotherapy in metastatic colorectal cancer.
Copur MS; Norvell M; Obermiller A
N Engl J Med; 2009 May; 360(20):2135; author reply 2135-6. PubMed ID: 19445033
[No Abstract] [Full Text] [Related]
20. Pathologic complete response to neoadjuvant FOLFOX in combination with bevacizumab in unresectable metastatic colorectal carcinoma.
Duffy A; Shia J; Huitzil-Melendez FD; Fong Y; O'Reilly EM
Clin Colorectal Cancer; 2008 Mar; 7(2):140-3. PubMed ID: 18501074
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
